Bookmark
Forward
QuickView for Vigabatrin (compound)
PubChem
| Name: | Vigabatrin |
|---|---|
| PubChem Compound ID: | 10219440 |
| Description: | An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID. (From Martindale The Extra Pharmacopoeia, 31st ed) |
| Molecular formula: | C6H11NO2 |
| Molecular weight: | 129.157 g/mol |
DrugBank
Identification
| Name: | Vigabatrin |
|---|---|
| Name (isomeric): | DB01080 |
| Drug Type: | small molecule |
| Description: | An analogue of GAMMA-AMINOBUTYRIC ACID. It is an irreversible inhibitor of 4-AMINOBUTYRATE TRANSAMINASE, the enzyme responsible for the catabolism of GAMMA-AMINOBUTYRIC ACID. (From Martindale The Extra Pharmacopoeia, 31st ed) |
| Brand: | 4-Amino-5-hexenoic acid, GVG, gamma-Vinyl GABA, Vigabatrine, Vigabatrine [French], Vigabatrinum [Latin], Vigabatrin [USAN:BAN:INN], Sabril (TN), 4-Aminohexenoic acid, Vigabatrina [Spanish] |
| Category: | GABA Agents, Enzyme Inhibitors, Anticonvulsants |
| CAS number: | 60643-86-9 |
Pharmacology
| Indication: | For use as an adjunctive treatment (with other drugs) in treatment resistant epilepsy, complex partial seizures, secondary generalized seizures, and for monotherapy use in infantile spasms in West syndrome. |
|---|---|
| Pharmacology: | Vigabatrin, is an anticonvulsant chemically unrelated to other anticonvulsants. Vigabatrin inhibits the catabolism of GABA. It is an analog of GABA, but it is not a receptor agonist. Vigabatrin irreversibly inhibits the enzyme GABA transaminase. |
| Mechanism of Action: |
It is believed that vigabatrin increases brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by irreversibly inhibiting enzymes that catabolize GABA (gamma-aminobutyric acid transaminase GABA-T) or block the reuptake of GABA into glia and nerve endings. Vigabatrin may also work by suppressing repetitiv...
show more » |
| Absorption: | Rapidly absorbed following oral administration. Food may slightly decrease the rate, but not the extent, of absorption. |
| Protein binding: | Little to none |
| Biotransformation: | Almost no metabolic transformation. Does not induce the hepatic cytochrome P450 system. |
| Route of elimination: | Vigabatrin is not significantly metabolized; it is eliminated primarily through renal excretion. |
| Half Life: | 5-8 hours in young adults, 12-13 hours in elderly. |
| Clearance: | 2.4 +/- 0.8 L/h [Infant] 5.7 +/- 2.5 L/h [Children] |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
